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Abstract
Ozenoxacin (OZN) belongs to a new generation of non-fluorinated quinolones for the topical
treatment of skin infections which has shown to be effective in the treatment of susceptible
and resistant Gram-positive cocci. The mutant prevention concentration (MPC) of ozenoxa-
cin, levofloxacin and ciprofloxacin was determined in quinolone-susceptible and -resistant
strains including methicillin-susceptible S. aureus, methicillin-resistant S. aureus, methicil-
lin-susceptible S. epidermidis and methicillin-resistant S. epidermidis with different profile of
mutation in the quinolone resistance determining regions (QRDR). The MPC value of OZN
for the methicillin-susceptible S. aureus strain susceptible to quinolones, without mutations
in QRDR, was 0.05 mg/L, being 280-fold lower than that observed with ciprofloxacin and
levofloxacin. In methicillin-susceptible and–resistant S. aureus strains with mutations in the
gyrA or/and grlA genes the MPC of OZN went from 0.1 to 6 mg/L, whereas the MPC of levo-
floxacin and ciprofloxacin was > 50 mg/L for the same strains. For methicillin-susceptible
and–resistant S. epidermidis the results were similar to those abovementioned for S.
aureus. According to our results, the MPC of OZN was far below the quantity of ozenoxacin
achieved in the epidermal layer, suggesting that the in vivo selection of mutants, if it occurs,
will take place at low frequency. Ozenoxacin is an excellent candidate for the treatment of
bacterial infections caused by susceptible and quinolone-resistant staphylococci isolated
usually from skin infections.
Introduction
Staphylococci are among the major groups of bacterial commensals isolated from skin and
mucous membranes of humans [1]. In addition, staphylococci is a predominant organism
causing infections in both community- and hospital-setting [2]. Specifically, Staphylococcus
aureus is the most common bacterium associated with skin infections, such as folliculitis and
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impetigo, affecting children more so than adults worldwide. However, it can also cause skin
and soft tissue infections in the hospitals as well as more severe infections such as pneumonia,
bacteremia, endocarditis and osteomyelitis [3, 4]. On the other hand, Staphylococcus epidermi-
dis is the most common microorganism on normal skin microbiota, being considered today as
an important opportunistic pathogen, and the most common source of infections on indwell-
ing medical devices [5, 6].
The treatment for these infections includes topical and/or oral antimicrobial agents,
according to the severity of the infection and damaged skin surface [7]. Topically administered
antibacterial agents include mupirocin, fusidic acid and retapamulin. Unfortunately, an
increasing number of Gram-positive pathogens, especially methicillin-resistant S. aureus
(MRSA), have developed resistance to topical antimicrobial agents typically used in clinical
practice, potentially limiting its overall efficacy [8]. Recently, a community-acquired methicil-
lin-resistant S. aureus strain carrying a plasmid conferring resistance to mupirocin and chlor-
hexidine has been reported, which reinforce the need for potential alternatives to threat
infections caused by these type of strains [9].
Nowadays, ozenoxacin (OZN) is a more recent alternative for topical treatment of infection
skin, with excellent clinical benefit in two recent Phase III trials [10]. OZN belongs to a new
generation of non-fluorinated quinolones, demonstrating excellent antibacterial activity in
vitro against Gram-positive cocci including resistant strains to other quinolones and low
capacity to select resistant mutant strains [11–15].
Quinolones bind to the complex DNA-DNA gyrase and DNA-topoisomerase IV, both of
these enzymes are involved in bacterial DNA synthesis [16]. However, the bactericidal effect of
these antibiotics is related, at least in part, to the accumulation of reactive oxygen species
(ROS) and oxidative damage of several macromolecules [17–19]. The main mechanism of
resistance to quinolones in staphylococci is associated with mutations in a specific region of
the gyrA (encoding the A subunit of DNA gyrase) and grlA (encoding the A subunit of topo-
isomerase IV) genes called the Quinolone Resistance-Determining Regions (QRDR). Several
mutations in a step-wise resistance acquisition can provide high-level of quinolone resistance
[20].
The appearance of resistant mutants in an infectious process is high and usually occurs ran-
domly and spontaneously [21]. For this reason, a drug concentration threshold above which
the bacterial cells require the presence of two or more mutations for their survival has been
designated. The antibiotic concentration above this threshold has been defined as the mutant
prevention concentration (MPC), which corresponds to the MIC of the less susceptible sub-
population and should severely restrict the selection of resistant mutants [22]. In the present
study, we have determined the mutant prevention concentration of ozenoxacin compared
with other quinolones, such as levofloxacin and ciprofloxacin for S. aureus and S. epidermidis
clinical isolates associated with skin infection.
Materials and methods
Fifteen quinolone-resistant and -susceptible strains with different genetic profiles in QRDR
region (previously characterized by PCR and sequencing) were analyzed. The strains were
selected from a previous study and obtained from the Clinical Microbiology Laboratory at the
Hospital Clinic in Barcelona, Spain [12]. The strains included: methicillin-susceptible S. aureus
(MSSA) (5 strains), methicillin-resistant S. aureus (3 strains), methicillin-susceptible S. epider-
midis (MSSE) (3 strains) and methicillin-resistant S. epidermidis (4 strains).The MPC of OZN
(Ferrer Laboratories), levofloxacin (LVX) and ciprofloxacin (CIP) (Sigma-Aldrich, St. Louis,
MO) were performed in triplicate and we used the technique described by our colleagues [23]
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with some modifications. Briefly, the microorganisms were cultured in Muller Hinton broth
(MHB, Becton Dickinson, Sparks, MD) and incubated for 24 h. Then, 1/10 dilution was made
in fresh culture medium to be subsequently incubated for 4 h at 37˚C with shaking. Aliquots of
1 ml were concentrated by centrifugation at 5,000 x g for 5 min, resuspended in 100 μl fresh
culture medium (approximately 1010−1011 cfu/mL) and inoculated onto Mueller-Hinton agar
(MHA, Oxoid, UK) plates containing increasing concentrations of fluoroquinolones from
concentrations lower than the MIC of each microorganism. The inoculum size was confirmed
by serial dilutions and plating on drug-free medium. The inoculated plates were incubated for
24–48 h at 37˚C and screened visually for growth. The MPC value corresponds to the concen-
tration that does not allow the recovery of bacterial colonies.
Results and discussion
According to the results obtained in this study, OZN has demonstrated lower values of MPC
compared to LVX and CIP in all strains of S. aureus and S. epidermidis included in the study,
as shown in Tables 1 and 2.
The MPC value of OZN for the MSSA strain susceptible to quinolones, without mutations
in QRDR, was 0.05 mg/L, being 280-fold lower than that observed with CIP and LVX (14 mg/
L). On the other hand, MSSA strain with 4 mutations in the QRDR showed a MPC value of
OZN of 6 mg/L, being more than 70-fold lower in comparison with other studied quinolones.
Similar results were observed in the group of MRSA strains, although unfortunately there
are no data available in MRSA susceptible to quinolones, without mutations in the QRDR.
MRSA with 4 mutations in the QRDR, showed a maximum value of MPC of OZN of 6 mg/L,
which was considerably lower than the MPC values of LVX and CIP (700 and 350 mg/L,
respectively).
Results of the MPC obtained for strains of S. epidermidis showed a similar behavior to that
observed in the strains of S. aureus. The MPC value of OZN was 0.025 and 0.05 mg/L, respec-
tively, for the MSSE and MRSE strains susceptible to quinolones, without QRDR mutations,
being lower than that observed with LVX (0.7–2 mg/L) and CIP (1.5–4 mg/L). On the other
hand, the MPC of OZN for MSSE and MRSE strains resistant to quinolones with 3 and 4
mutations in the QRDR was 6 mg/L in both groups of strains, being significantly lower than
LVX and CIP, whose value of concentration for preventing the appearance of resistant
mutants was 750 and 900 mg/L and 300 and 250 mg/L, respectively.
According to our observations, after exposing a high bacterial inoculum (1011cfu/mL) to
increasing concentrations of OZN, LVX or CIP, it was possible to recover subpopulations that
survived at a higher concentration than the initial MIC in both groups of methicillin- and
quinolone-susceptible and -resistant staphylococci strains. However, if we compare the MPC
values of both species, we observed that OZN value fluctuated between 0.025 and 6 mg/L,
being the last value observed in a strain with 4 mutations in the QRDR. In other words, only 6
mg/L of OZN are needed to inhibit the growth of the most resistant subpopulation in a high
bacterial inoculum.
On the other hand, if we compare the MPC value of the comparative quinolones in the
same group of strains, we observe that this value fluctuated between 0.6 and 900 mg/L for LVX
and 0.9 and 650 mg/L for CIP, which are considerably higher values than those observed with
OZN.
Several studies in quinolones of fourth generation have reported generally similar results to
ours although with some discrepancies for some strains. For example, Metzler and colleagues
[24] reported the MPCs values of different fluoroquinolones for MSSA and MRSA strains. In
this study, LVX MIC90 for MSSA strains was 0.25 mg/L and the MPC90 of 1 mg/L, being lower
Mutant prevention concentration of ozenoxacin in staphylococci
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than the MPC of LVX found in our study for wild-type MSSA strain (without mutation in
QRDR). However, the MIC90 of LVX for MRSA was>16 mg/L and the MPC90 of 128 mg/L,
being higher than the one strain found in our study (MIC of LVX of 16 mg/L and MPC of 85
mg/L). Additionally, studies described by Liu and colleagues [25] showed that when the MIC of
LVX for MRSE strains was 0.25 mg/L, the obtained MPC value was between 4–8 mg/L, similar
to the results in our study. On the other hand, studies with delafloxacin a novel fluoroquinolone,
showed that the MPC values ranged from one to four times the initial MIC and were markedly
lower (8- to 32-fold) than the MPCs for the other quinolones included in that study. This fact is
an excellent characteristic for an antimicrobial agent. However, as the analysis was only per-
formed on MRSA strains, it is not possible to completely compare with our results [26].
In conclusion, OZN shows a strong ability to restrict the development of resistant strains as
following only a slight increase in OZN concentration, the eradication of the most resistant
subpopulations with possible multiple mutations in the QRDR occur. This suggests that the in
vivo mutant selection, if it occurs, will take place at low frequency. In addition, the MPC values
Table 1. Activities of ozenoxacin, levofloxacin and ciprofloxacin against isolates of S. aureus.







4–149 WM 2 WM OZN 0.0039 0.05
LEV 0.25 14
CIP 0.38 14
440 S84L WM OZN 0.125 0.8
LEV 64 110
CIP 64 125
8901 WM S87L OZN 0.008 0.1
LEV 0.5 14
CIP 2 20
176 S84L/S85P WM OZN 0.5 1.2
LEV 128 400
CIP 256 550




108 S84L WM OZN 0.06 0.6
LEV 16 85
CIP 16 75
823 S84L WM OZN 0.125 0.6
LEV 64 200
CIP 256 400
126 S84L/E88K S80F/E84V OZN 2 6
LEV 512 700
CIP 256 350
1 Mutant prevention concentration (MPC). This parameter was defined to characterize the capacity to prevent/severely restrict the emergence of drug-resistant mutants
[22].
2 WM, without mutation in the QRDR
3 No data on MRSA WM are available
https://doi.org/10.1371/journal.pone.0223326.t001
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found in our study was in all the cases below the concentration of ozenoxacin achieved in the
epidermis (of 22 mg/L after 3 days, twice a day application [27], a quantity of OZN far higher
than the maximal range of MIC and MPC for resistant staphylococci strains detected in all the
performed in vitro studies. These results are probably due to its potent activity linked to the
strong inhibition of both protein targets and to the rapid accumulation inside bacteria [11,28,
29]. For this reason, OZN is an excellent candidate for the treatment of bacterial infections
caused by susceptible and methicillin-resistant and/or quinolone-resistant Gram-positive





Part of this work was presented at the Fifty-three Interscience Conference on Antimicrobial
Agents and Chemotherapy (ICAAC), Denver, CO, USA, 2013 (Abstract C1-522b) and XII
Table 2. Activities of ozenoxacin, levofloxacin and ciprofloxacin against isolates of S. epidermidis.







HCL43141 WM 2 WM OZN 0.0078 0.025
LEV 0.125 0.7
CIP 0.19 1.5
HCL 46313 WM S80Y OZN 0.0078 0.025
LEV 0.125 0.6
CIP 0.19 0.9




7602 WM WM OZN 0.03 0.05
LEV 0.5 2
CIP 1 4
6902 S84F WM OZN 0.031 0.1
LEV 2 4
CIP 2 20
FG012 S84F S80F OZN 0.12 0.3
LEV 32 80
CIP 128 250
FG013 S84Y/E88K S80F/D84Y OZN 2 6
LEV 512 900
CIP 128 250
1 Mutant prevention concentration (MPC). This parameter was defined to characterize the capacity to prevent/severely restrict the emergence of drug-resistant mutants
[22]
2 WM, without mutation in the QRDR
https://doi.org/10.1371/journal.pone.0223326.t002
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